Back to News
Market Impact: 0.25
RiboX Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RXRG001 for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
Source: Business Wire
Healthcare & BiotechRegulation & Legislation
RiboX Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RXRG001, its treatment candidate for radiation-induced xerostomia and hyposalivation. The designation may expedite development and regulatory engagement for the therapy, representing a positive clinical and regulatory milestone for the company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- Piero Cipollone: Interview with Milano Finanza
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Alternative Data Due Diligence for Institutional Investors
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors